Organisation paid for research Program year 2025 Source: CMS Open Payments

Infinity Medical Research Inc

Neither a doctor nor a teaching hospital

Research payments

$990,800

288 payments

Through program year 2025, Infinity Medical Research Inc is reported as receiving $990,800 in research payments, across 288 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $54,235 20
2024 Research $229,801 36
2023 Research $82,359 17
2022 Research $46,617 17
2021 Research $60,885 19
2020 Research $98,183 75
2019 Research $418,719 104

Breakdown

Who paid Research payments · program years 2019–2025
  1. Sanofi US Services Inc. $294,818 21 payments
  2. GlaxoSmithKline, LLC. $257,385 47 payments
  3. Novo Nordisk AS $106,939 131 payments
  4. Chiesi USA, Inc. $94,653 14 payments
  5. Teva Pharmaceuticals USA, Inc. $91,873 42 payments
  6. AstraZeneca Pharmaceuticals LP $68,893 5 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $33,581 4 payments
  8. Regeneron Pharmaceuticals, Inc. $32,833 9 payments
  9. Genentech, Inc. $9,505 4 payments
  10. Jazz Pharmaceuticals Inc. $320 11 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3, 52-Week, Randomized, Double-Blind, Placebo-Controlled, Para $164,501 27 payments
  2. A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of SAR440340, in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) $137,456 8 payments
  3. Nn9838-4433 $102,078 128 payments
  4. A 52-Week, Randomised, Double-Blind, Double-Dummy, Parallel Group, Mul $92,884 20 payments
  5. A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of SAR440340, in Patients With Moderate-to-severe Chronic O $91,192 5 payments
  6. A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) $78,106 11 payments
  7. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia $48,258 21 payments
  8. Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos) $44,432 1 payment
  9. Tio & Olo versus PBO stratified by PIFR $33,258 3 payments
  10. A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Dupilumab on Exercise Capacity in Patients With Moderate-to-Severe Asthma $32,833 9 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record